Ernexa Therapeutics Inc. (ERNA) Notes Payables (2013 - 2025)

Ernexa Therapeutics' (ERNA) quarterly Notes Payables came in at $2.2 million in Q1 2025, down 54.32% on a QoQ basis from $4.9 million in Q3 2024.

Ernexa Therapeutics Inc. (ERNA) Notes Payables (2013 - 2025) Analysis & Trends

Ernexa Therapeutics (ERNA) has 4 years of Notes Payables data on file, last reported at $2.2 million in Q1 2025.

Quarterly Notes Payables changed N/A year-over-year to $2.2 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $2.2 million (changed N/A YoY) and the FY2013 annual result came in at $631000.0, changed N/A from the prior year.
Notes Payables slipped to $2.2 million in Q1 2025, from $4.9 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $4.9 million in Q3 2024 to a low of $2.2 million in Q1 2025.

Download Data